drugset / Trial / NCT00783003

A Study to Assess the Safety and Pharmacokinetics of Inhaled Doses of GSK233705 and GW642444 in Healthy Subjects

NCT00783003

Phase 1 Completed 16 enrolled GlaxoSmithKline
RandomizedCrossoverQuadruple-blindOther

Summary

GW642444 and GSK233705 are in development for treatment of Chronic Obstructive Pulmonary Disease. Development of these two inhaled drugs as a combination therapy would have potential for improved patient benefit as they both work through different mechanisms and the combined bronchodilatory effect might be additive. This study will look at the this combination, for the first time, in healthy Japanese subjects.

Timeline

Start
2008-11-10
Primary completion
2009-02-06
Completion
2009-02-06

Drugs

EvaluationDrugModalityDoseRoute
Subject DAROTROPIUM Small molecule Inhaled
Subject Vilanterol Other / unclassified Inhaled